1stOncology™: Cancer Intelligence Service – Page 13524 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Oragenics Inc. to Present at NobleCon15 on January 28, 2019

On January 25, 2019 Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), reported that Alan Joslyn, Ph.D., president and CEO of Oragenics will be a featured presenter at NobleCon15 – Noble Capital Markets’ Fifteenth Annual Investor Conference on January 28th at 10:30 AM Eastern Standard Time (Press release, Oragenics, JAN 25, 2019, View Source [SID1234532908]). The conference is being held at the W Hotel, Fort Lauderdale, Florida. Dr. Joslyn will provide an overview of the company’s business model and growth strategy and will be available for one-on-one meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A high-definition, video webcast of the presentation will be available the following day on Oragenics’ web site View Source, and as part of a complete catalog of presentations available at Noble Capital Markets’ websites: www.noblecapitalmarkets.com, and www.nobleconference.com. The webcast and presentation will be archived on the company’s website and on the Noble websites for 90 days following the event.

MacroGenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA

On January 25, 2019 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on its Phase 1 monotherapy and combination studies of MGD009, a B7-H3 × CD3 bispecific DART molecule (Press release, MacroGenics, JAN 25, 2019, View Source [SID1234532906]). Enrollment of new patients in the U.S. has been cleared to proceed with these trials. MacroGenics previously announced on December 7, 2018, that the FDA had placed the program on partial clinical hold following MacroGenics’ reporting of hepatic adverse events on the MGD009 trials to the FDA. During the partial clinical hold, previously enrolled study participants were allowed to continue to receive drug at their pre-assigned dose.

"The MacroGenics team worked diligently and rapidly to provide a comprehensive response to the FDA in late December. As a result, we have been able to resolve the partial clinical hold without significant delay to this clinical program," stated Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "The partial clinical hold did not involve our other B7-H3 programs, and, in fact, during the partial hold, we completed enrollment of the first dose escalation cohort for MGC018, our B7-H3-targeted ADC."
About MGD009
MGD009 is a humanized, bispecific DART molecule that recognizes both B7-H3 and CD3 and has a prolonged serum half-life. B7-H3 is a member of the B7 family of molecules involved in immune regulation and is over-expressed on a wide variety of cancer cells, including cancer stem cells, as well as on the supporting tumor vasculature and underlying tissues, or stroma. The intended mechanism of action of MGD009 is its ability to redirect T cells, via their CD3 component, to kill B7-H3-expressing cells.

In addition to MGD009, MacroGenics’ comprehensive B7-H3 franchise includes enoblituzumab, an Fc-optimized monoclonal antibody, as well as MGC018, an antibody-drug conjugate. These clinical molecules target B7-H3. MacroGenics retains worldwide rights to its franchise of three B7-H3-based molecules.

NuCana plc Announces Withdrawal of Public Offering of ADSs

On January 25, 2019 NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company (the "Company") focused on significantly improving treatment outcomes for patients with cancer, reported that it has withdrawn the proposed underwritten offering of American Depositary Shares ("ADSs") (Press release, Nucana BioPharmaceuticals, JAN 25, 2019, View Source [SID1234532903]). The Company believes it is not in the best interest of its shareholders to raise equity capital in the current market environment. The Company remains well capitalized with a cash position of approximately £77 million as of December 31, 2018 to fund its key programs.

Actinium Pharmaceuticals, Inc. to Present at Noble Capital Markets’ 15th Annual Investor Conference

On January 25, 2019 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) reported that it will present at NobleConXV – Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Tuesday, January 29th at 12:30 pm EST (Press release, Actinium Pharmaceuticals, JAN 25, 2019, View Source [SID1234532902]). Actinium is the only company with a multi-disease, multi-target, drug development pipeline focused on targeted conditioning via its ARC or Antibody Radiation Conjugate Approach. Details of Actinium’s presentation are as follows:

Date: Tuesday, January 29th
Time: 12:30 PM ET
Room: Studio 4
Venue: W Hotel, Fort Lauderdale, Florida

Members of Actinium’s Executive team will be available for 1-on-1 meetings with conference attendees. Those interested in scheduling a meeting with Actinium may do so through the conference’s system View Source or by contacting Steve O’Loughlin, Actinium’s Principal Financial Officer via email to [email protected].

Allergan Announces Increased Quarterly Dividend and Annual General Meeting of Shareholders Date

On January 25, 2019 Allergan plc (NYSE: AGN) reported that its Board of Directors has approved an increase in the Company’s quarterly cash dividend for 2019 to $0.74 per ordinary share (Press release, Allergan, JAN 25, 2019, View Source [SID1234532901]). The Board declared a cash dividend for the first quarter of 2019 to be paid on March 15, 2019 to shareholders of record at the close of business on February 15, 2019.

"Allergan’s increased dividend for 2019 demonstrates our confidence in our long-term business strategy and our commitment to executing on our capital allocation priorities. We remain committed to increasing our dividend annually," said Brent Saunders, Chairman and CEO of Allergan.

Allergan also announced that its 2019 Annual General Meeting of Shareholders will be held on May 1, 2019 in Dublin, Ireland. The Company’s Board of Directors has set the close of business on March 5, 2019 as the record date for determining shareholders eligible to vote at the meeting.